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Abstract
Background: Detailed knowledge of the evolutionary potential of polymorphic sites in a viral protein is important
for understanding the development of drug resistance in the presence of an inhibitor. We therefore set out to analyse
the molecular evolution of the HIV-1 subtype B integrase at the inter-patient level in Germany during a 20-year period
prior to the first introduction of integrase strand inhibitors (INSTIs).
Methods: We determined 337 HIV-1 integrase subtype B sequences (amino acids 1–278) from stored plasma samples
of antiretroviral treatment-naïve individuals newly diagnosed with HIV-1 between 1986 and 2006. Shannon entropy was
calculated to determine the variability at each amino acid position. Time trends in the frequency of amino acid variants
were identified by linear regression. Direct coupling analysis was applied to detect covarying sites.
Results: Twenty-two time trends in the frequency of amino acid variants demonstrated either single amino
acid exchanges or variation in the degree of polymorphy. Covariation was observed for 17 amino acid variants with a
temporal trend. Some minor INSTI resistance mutations (T124A, V151I, K156 N, T206S, S230 N) and some INSTI-selected
mutations (M50I, L101I, T122I, T124 N, T125A, M154I, G193E, V201I) were identified at overall frequencies >5%. Among
these, the frequencies of L101I, T122I, and V201I increased over time, whereas the frequency of M154I decreased.
Moreover, L101I, T122I, T124A, T125A, M154I, and V201I covaried with non-resistance-associated variants.
Conclusions: Time-trending, covarying polymorphisms indicate that long-term evolutionary changes of the HIV-1
integrase involve defined clusters of possibly structurally or functionally associated sites independent of selective
pressure through INSTIs at the inter-patient level. Linkage between polymorphic resistance- and non-resistance-
associated sites can impact the selection of INSTI resistance mutations in complex ways. Identification of these sites can
help in improving genotypic resistance assays, resistance prediction algorithms, and the development of new integrase
inhibitors.
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Background
The HIV-1 integrase catalyses the integration of the
reverse transcribed viral DNA into the host genomic
DNA via a two-step process. In its active form the inte-
grase forms a tetramer. The monomeric enzyme con-
sists of 288 amino acids (aa) and contains three
functional domains: the N-terminal zinc-binding
domain (NTD, aa 1–49), the central catalytic core
domain (CCD, aa 50–212), and the C-terminal DNA-
binding domain (CTD, aa 213–288) [1–4]. Each region
comprises motifs essential for the proper function of
the enzyme, e.g. the zinc finger motif H12-H16-C40-
C43 in the NTD, the active site D64-D116-E153 in the
CCD, and the minimal nonspecific DNA-binding region
ranging from I220 to D270 in the CTD [2–6].
Raltegravir was the first integrase strand inhibitor
(INSTI) to be approved in Europe in 2007, followed by
elvitegravir in 2012 and dolutegravir in 2014. Bictegravir
[7] and cabotegravir [8] are in clinical trial development.
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INSTIs target the CCD, thereby inhibiting the strand
transfer of the double-stranded viral DNA into the host
genome [1]. Various allosteric inhibitors of integrase
(ALLINIs), which modulate integrase multimerisation
[9] and interfere with the cellular transcription factor
LEDGF/p75 [10] are in development but have not so far
made it further than Phase I clinical trial [11].
Due to its high rate of replication, mutation, and
recombination, HIV is a virus of high genetic variabil-
ity. The viability of virus variants in turn is limited by
structural and functional constraints. At the same time,
variants in the viral quasispecies can be selected by the
pressure of the human immune system [12, 13] or anti-
retroviral treatment (ART) [14, 15]. In general, the HIV
diversity at the intra-patient level increases during the
course of infection [16] driven by both drift and selec-
tion [17]. During transmission to a new host, several
stochastic and selective bottlenecks reduce the viral di-
versity to a few variants [18], and factors that contrib-
ute to shaping the HIV diversity at the inter-patient
level are extensively discussed [19–24].
Naturally occurring polymorphisms can affect the gen-
etic barrier to drug resistance by influencing the selec-
tion of resistance mutations, enzymatic activity, and
replicative capacity [22, 25, 26]. Epistatic interactions be-
tween polymorphisms can further modulate viral fitness
and the development of drug resistance in complex ways
and have been shown to play an important role in the
HIV-1 protease and reverse transcriptase [27–30]. Thus,
to understand the selection of resistant variants in the
presence of INSTIs, it is important to investigate the
evolutionary dynamics of the polymorphic sites in the
integrase.
The prevalence of HIV-1 integrase polymorphisms and
INSTI resistance mutations has been investigated before
in INSTI-naïve individuals [26, 31–35] and ART-naïve
individuals [35–40]. However, time trends and covari-
ation of complex mutation patterns preceding the avail-
ability of INSTIs have not so far been analysed. The aim
of this study was to investigate covarying clusters of nat-
urally occurring resistance- and non-resistance-
associated amino acid variants and their frequencies over
time at the inter-patient level to consider their potential
relevance for INSTI resistance. To this end, HIV-1
integrase sequences were obtained from samples of
ART-naïve individuals newly diagnosed with HIV-1 be-
tween 1986 and 2006, a 20-year period prior to the first
approval of INSTI in Germany [41].
Methods
Study population
Plasma samples from individuals newly diagnosed with
HIV-1 between 1986 and 1996 (N = 167) were archived
at the former diagnostic unit of the National AIDS
Centre in Germany and stored at −40 °C. The date of
HIV-1 diagnosis is the same as the plasma sampling date
for the HIV-1 integrase genotyping. Plasma samples
from individuals newly diagnosed with HIV-1 between
1997 and 2006 (N = 170) were collected for the German
HIV-1 Seroconverter Study [42–45] and stored at −70 °
C. These plasma samples were taken within 12 months
after diagnosis. In total, the study population comprised
337 individuals (Table 1).
HIV-1 integrase genotyping
Viral RNA from 500 μl plasma was pelleted by centri-
fugation (20,800 g, 90 min, 4 °C) and then isolated
using the Viral RNA Mini Kit (Qiagen, Germany) ac-
cording to the manufacturer’s instructions. Reverse
transcription and polymerase chain reaction were per-
formed using the OneStep RT-PCR kit (Qiagen,
Germany) with primers 5′-INT (5′- ATT GGA GGA
AAT GAA CAA GT -3′; nucleotides (nt) 4173–4192,
Acc. K03455) and 3p31as (5′- ATC CTG TCT ACY
TGC CAC ACA A -3′; nt 5066–5087, Acc. K03455)
[37]. Amplicons were purified (QIAquick spin PCR
purification kit, Qiagen, Germany) and sequenced by
cycle-sequencing (ABI Big Dye 3.1, Gene Amp
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Applied Biosystems PCR System 9700, Thermo Fisher
Scientific, Germany) with the primers listed above
and the additional primers F2 s (5′- TAA GAC AGC
AGT ACA AAT GGC AG -3′; nt 4745–4767, Acc.
K03455) and F3as (5′- GCT GTC CCT GTA ATA
AAC CCG -3′; nt 4899–4919, Acc. K03455). Sequen-
cing was performed on an ABI Prism 310 capillary
sequencer (Thermo Fisher Scientific, Germany), and
SeqMan Pro (Lasergene v10.0.1, DNASTAR, USA)
was used for sequence analysis. This genotyping assay
had a detection limit of 103 copies/ml for HIV-1 sub-
type B and yielded a 915 bp amplicon spanning HIV-
1 integrase bp 1–278. Only subtype B strains were in-
cluded in the analyses. The HIV-1 subtype was




Major INSTI resistance mutations (T66I, E92Q, F121Y,
Y143CHR, S147G, Q148HKR, N155H) that confer sub-
stantial phenotypic resistance to at least one of the cur-
rently approved INSTI as well as minor INSTI
resistance mutations (T66AK, L74 M, E92G, T97A,
E138AK, G140AS, R263K) that increase INSTI resist-
ance and/or viral replication capacity were identified ac-
cording to the IAS-list [46]. In addition, the following
minor INSTI resistance mutations according to the
current definitions of the resistance prediction algorithm
HIVdb (http://hivdb.stanford.edu, version March 2,
2017), ANRS (http://www.hivfrenchresistance.org, ver-
sion no. 26, September 2016), HIV-GRADE (http://
www.hiv-grade.de, version January 16, 2017), and Rega
(https://rega.kuleuven.be/cev/avd/software/rega-algo-
rithm, v9.0.1, October 29, 2013) were considered: A49G,
H51Y, V54I, L68IV, L74I, E92V, Q95K, H114Y, G118R,
S119R, T124A, A128T, E138T, G140C, Y143AGS,
P145S, Q146IKLPR, Q148EG, V151AIL, S153FY,
N155ST, K156 N, E157Q, G163KR, T206S, S230GNR,
D232N, V260I. Moreover, INSTI-selected mutations that
were observed in vitro or in vivo were investigated [47,
48]: M50I, G59E, I60L, I72A, Q95T, L101IY, T112S,
F121Y, T122I, T125A, E138D, Y143K, Q148N, M154I,
I162M, G163E, Q177R, G193E, V201I, I203M, I204T.
Assessment of phylogenetic bias
A unique anonymising code provided with the
mandatory report of newly HIV-1 infected cases to the
Robert Koch-Institute ensured that only one HIV-1 se-
quence per patient was included in our dataset. How-
ever, to investigate whether our results were biased by
the overrepresentation of phylogenetically closely related
sequences (i.e. sequences originating from direct trans-
mission events) we identified clusters of sequences with
a very small phylogenetic distance and replaced them
with one representative sequence (the sequence from
the patient who was diagnosed first). For clustering, a
multiple sequence alignment (MSA) including an HIV-1
group N reference sequence (Acc. AJ006022) was gener-
ated with clustalW (BioEdit, v7.2.5, Tom Hall) and end-
trimmed to nt 4230–5064 (Acc. K03455). We computed
a maximum likelihood phylogeny with 500 times non-
parametric bootstrap with replacement using the pro-
gram RAxML [49]. The HIV-1 group N sequence was
used to root the maximum likelihood tree. Applying the
program Transmic [50], a set of phylogenetically closely
related sequences was identified if the mean of all pair-
wise patristic distances did not exceed a threshold of
0.015 expected nucleotide substitutions per site and the
most recent common ancestor node had a bootstrap
support of 0.9 [50, 51]. We detected 11 clusters, each
comprising two sequences. The final reduced dataset
consisted of 326 sequences. All analyses were then
performed with the full dataset and the reduced dataset
to assess any potential bias. All reported results were
confirmed on the basis of both datasets while all
numbers reported in the results section are given for the
full dataset.
Amino acid variability
MSAs for the full (337 sequences) and the reduced (326
sequences) dataset were generated with clustalW (BioE-
dit, v7.2.5, Tom Hall) and end-trimmed to nt 4230–5064
(Acc. K03455). The nucleotide sequences were then
translated into amino acid sequences. Nucleotide se-
quence ambiguities of codons were resolved during
translation. An X was assigned if multiple amino
acids resulted from the translation of codons contain-
ing nucleotide sequence ambiguities to avoid consid-
eration of amino acid variants only present in
mixtures due to PCR and sequencing errors. The
frequencies of amino acids at positions 1 to 278 of
the HIV-1 integrase were calculated. A position was
defined to be polymorphic if, on the basis of the full
and the reduced dataset at this position, a total of 1%
or more amino acid variants were present when com-
pared to the consensus B sequence (http://hivdb.stan-
ford.edu/pages/documentPage/consensus_amino_acid_-
sequences.html). All other positions were defined as
conserved.
We also analysed the Shannon entropy Ei, which
quantifies the degree of variability at a single amino acid
position i [1,278], according to
Ei ¼ −
X
x P Xi ¼ xð Þ log2P Xi ¼ xð Þ
where P(Xi = x ) denotes the probability of observing the
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particular amino acid x at position i [52]. A high value
of entropy Ei indicates high amino acid variability at
position i.
Amino acid time trends
The samples were grouped into five time periods
(1986–1989, 1990–1994, 1995–1998, 1999–2002, and
2003–2006) to obtain a more homogenous distribu-
tion and to render the time trend analyses more
robust (Additional file 1: Table S1). Next, we calcu-
lated the frequencies of all amino acids at positions 1
to 278 of the HIV-1 integrase within the periods. We
then fitted a linear regression by minimizing the sum
of least square deviation between detected and pre-
dicted frequencies y and f(a, b) for each period i
according to
a;bf g ¼ argmin
X
i
f a; b; xið Þ−y xið Þð Þ2
with fi(a, b, xi) = a ∙ xi + b where a denotes the slope and
b the intersect of the linear function. The variable xi
denotes the distance of the centre of period i [in years]
to the centre of the first period. In order to detect sig-
nificant time trends, we generated 10,000 bootstrap
samples by drawing sequences from the original
sequence set with replacement. For each resampled set,
we computed mutation frequencies and performed the
linear regression as described above. Raw P values were
then computed from the bootstrap distribution of fitted
slopes a in analogy to Katchanov et al. [53], i.e. we
computed Pþ ¼ #a≤0:00110000 to test whether the frequency of
that mutation is significantly increasing by at least 0.1%
per year (H0 : a ≤ 0.001 vs. H1 : a > 0.001) and conversely
P− ¼ #a≥−0:00110000 to assess whether it is significantly
decreasing by at least 0.1% per year (H0 : a ≥ − 0.001 vs.
H1 : a < − 0.001). P values (P =min(P
−, P+)) were subse-
quently corrected for multiple testing using the false
discovery rate (FDR) method by Benjamini-Hochberg
[54]. Time trends were considered significant if they
were identified on the basis of the full and the reduced
dataset with a FDR corrected P < 0.05.
Amino acid covariation
In order to determine if amino acid positions are co-
varying, we applied direct coupling analysis where dir-
ect correlations are disentangled from transitive
correlations. We computed evolutionary coupling
terms ecij using the recently developed plmc tool
(https://github.com/debbiemarkslab/plmc) [55]. This
tool infers couplings by fitting a Potts model to the
MSA using a pseudo likelihood approach with L2
regularisation. We used default regularisation parame-
ters of λ1 = 0.01 and λ2 = 100 for single site
contributions and direct couplings terms eij(α,β),
respectively. To correct for a phylogenetic bias by
reweighting neighbouring sequences, we chose the de-
fault parameter θ = 0.01. Ambiguous amino acids (X)
were discarded during inference. As expected, the
inferred coupling terms are approximately normally
distributed with mean 0 and standard deviation 1/λ2.
The direct coupling terms eij(α,β) describe the direct
correlation of two amino acids α and β at positions i and
j. The overall interaction of two positions i and j are
given by the evolutionary coupling term ecij, which is the
Frobenius norm of the direct coupling terms
∥eij∥2 ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃX
α; β eij α; βð Þ2
r
with average product correction (APC), to suppress
phylogenetic bias effects [56]:
ecij ¼ ∥eij∥2−∥ei∥2∙∥ej∥2∥e∥2 :
To identify significant coupling terms, z-scores were
computed according to
Zscoreij ¼ eij−μ eð Þ
σ eð Þ
where μ(e∗∗) and σ(e∗∗) denote the mean and standard
deviation of the estimated evolutionary coupling terms
between all position pairs i < j. Z-scores were then con-
verted into P values and corrected for multiple testing
using the Benjamini-Hochberg method [54]. We used
P < 0.005 to detect significant couplings [57], which cor-
responds to a Bayes factor of 14 typically used in Bayes-
ian inference [58].
To ensure the robustness of the statistical inference,
Halsey et al. [59] recently proposed to combine power
analysis with P value based statistical analysis. In line
with these recommendations, we generated 1000
MSAs by sampling sequences with replacement from
the original alignment. For each resampled MSA, we
inferred the coupling terms and performed the statis-
tical tests as outlined above. In line with Halsey’s rec-
ommendations, we only reported coupling terms that
were significant in at least 95% of the resamplings,
i.e. where the respective test power was >0.95. An
interactive plot to explore the detailed results of the
direct coupling analysis was generated using the
EVZoom tool (https://github.com/debbiemarkslab/
EVzoom) and can be accessed through http://page.-
mi.fu-berlin.de/msmith/couplings_integrase.html.
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Results
Characteristics of the study population
All 337 individuals were newly diagnosed with HIV-1,
ART-naïve, and infected with an HIV-1 subtype B
strain. The median age at HIV-1 diagnosis was 32
(inter-quartile range 27–38) years. Most individuals
were male (297/337, 88.1%), 11.0% (37/337) were
female, and for 0.9% (3/337) the gender was not doc-
umented. The most common transmission group was
men having sex with men (220/337, 65.3%), followed
by 14.8% heterosexual transmission (50/337) and
14.2% injection drug users (48/337). For 5.6% (19/
337) of the individuals the risk factor for transmission
was unknown.
Frequency of INSTI resistance mutations
As expected, no major INSTI resistance mutations were
detected in this ART-naïve study population from the
period prior to INSTI release. Moreover, all major INSTI
resistance-associated positions were fully conserved, and
amino acids at these positions corresponded to the
respective INSTI-sensitive consensus B amino acids.
However, some minor INSTI resistance mutations and
INSTI-selected mutations were identified (Table 2).
Amino acid variability
Eighty-six polymorphic sites (30.9%) were observed
within the 278 amino acid positions examined in the
HIV-1 integrase. Proportionately, most polymorphic po-
sitions were found in the NTD (20/49, 40.8%). There
were equal proportions of polymorphic sites within the
CCD (47/163, 28.8%) and the CTD (19/66, 28.8%)
(Fig. 1). The highest amino acid variability with entropies
>0.75 was found in the NTD at positions 11 and 17 as
well as in the CCD at positions 72, 101, 119, 122, 124,
125, 154, and 201 (Fig. 2).
The zinc finger motif (H12-H16-C40-C43), the active
site (D64-D116-E153), the multimerisation motif
(K186-R187-K188), and most sites interacting with the
cellular cofactor LEDGF/p75 or within the minimal
nonspecific DNA binding region were conserved.
Nevertheless, positions 125, 165, 167, 171, 172, and
173, involved in binding LEDGF/p75, were polymorphic
with entropies up to 0.96. Likewise, within the minimal
nonspecific DNA binding region positions 220–222,
227, 230, 232, 234, 251–256, and 265 exhibited entro-
pies up to 0.66 (Fig. 2).
Amino acid time trends
Twenty-two significant time trends in amino acid
frequencies were discovered at 13 polymorphic posi-
tions. Proportionally, most of these sites were located in
the CCD (9/163, 5.5%), followed by location in the NTD
(2/49, 4.1%) and the CTD (2/66, 3.0%) (Fig. 3).
At nine positions (6, 11, 72, 101, 135, 154, 165, 201,
265) an amino acid exchange between two variants was
identified. In contrast, at sites 119 and 124 increasing
polymorphy was observed since variants decreased in
frequency without being replaced by another variant. Fi-
nally, variants 122I and 256E increased in frequency
without replacing another variant, although a decrease
of T122 and D256 was observed that was close to statis-
tical significance (Fig. 3).
Table 2 Overall frequency (%) of minor INSTI resistance
mutations and INSTI-selected mutations
Overall frequency (%) of
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Variants L101I, T122I, and V201I with increasing fre-
quency as well as M154I with decreasing frequency were
associated with INSTI resistance (Fig. 3).
Amino acid covariation
Overall, 42 significant couplings were identified (Table 3).
10 couplings appeared within the NTD, 10 within the
CCD, and two within the CTD. 13 couplings were ob-
served between the NTD and the CCD, five between the
CCD and the CTD, and two between the NTD and the
CTD. In total, 25 and 28 couplings involved at least one
position within the NTD and the CCD, respectively
(Fig. 4).
The LEDGF/p75-binding sites 125 and 165 were ob-
served in one coupling each. Nine couplings involved
sites 222, 234, 253, 256, or 265 of the minimal nonspe-
cific DNA-binding region (Table 3).
17 amino acid variants with temporal trend were
found to covary with other time-trending variants. The
individual time trends were generally compatible, i.e.
both time trends were concordant if the coupling terms
were positive and discordant if the coupling terms were
negative (Table 4).
Two minor INSTI resistance mutations (T124A,
E157Q) and five INSTI-selected mutations (L101I, T122I,
T125A, M154I, V201I) covaried with non-resistance-
associated variants (Table 4).
Discussion
Our analyses could confirm and considerably extend
previously published results based on INSTI-naïve [26,
31–35] or ART-naïve [35–40] study populations that ei-
ther focused on HIV-1 subtype B [31, 36, 38] or included
various HIV-1 group M subtypes [26, 32–35, 37, 39, 40].
We restricted our analyses to HIV-1 subtype B strains
because these are predominant in Germany [43–45] and
because different HIV-1 subtypes have different consen-
sus amino acids at some sites, which can bias the degree
of variability when compared to consensus B [33, 35].
We found the highest amino acid variability determined
by entropy, time trends, and direct coupling analysis
within the CCD, the NTD, and between CCD and NTD.
Sites important for enzymatic activity were in general con-
served, however, some positions involved in binding the
cellular cofactor LEDGF/p75 (sites 125, 165) and within
the minimal nonspecific DNA binding region (sites 220,
230, 232, 234, 256, 265) were polymorphic with an overall
variability ≥5%. Covariation between positions 125, 165,
256, or 265 and other sites was observed, and the DNA-
binding site 234 covaried with the DNA-binding site 253.
The most frequent substitutions were T125A, V165I,
I220L, S230 N, D232E, L234I, D256E, and A265V. All of
them occurred within the same biochemical class of
amino acids, with the exception of T125A that represents
a switch from a hydrophilic to a hydrophobic amino acid.
Fig. 2 Levels of Shannon entropy at amino acid positions 1–278
of the HIV-1 integrase. Positions with entropy levels >0.75 and
the three functional domains of the integrase are indicated
Fig. 1 Ribbon model of the HIV-1 integrase monomer from two viewpoints. The model was constructed in PyMol [67] as an overlay of
protein database structures 1ex4 [3] and 1k6y [4]. The NTD (aa 1–49) is coloured yellow, the CCD (aa 50–212) green, and the CTD (aa
213–288) red. Polymorphic sites are coloured grey
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The effect of this switch is not known and should be
investigated experimentally. A time trend in frequency
was observed for variants T125A, D256E, and A265V.
The knowledge about the variability of the integrase
should be taken into account for the design of geno-
typic resistance assays.
Most time trends were based on an exchange of two
amino acids, however, a general diversification was
observed at sites 119 and 124. 17 out of 22 amino acid
variants with increasing or decreasing frequency covar-
ied among each other. In general, we observed a con-
cordant time trend for pairs with a positive direct
coupling term and a discordant time trend for pairs
with a negative direct coupling term. Exceptions to this
rule were couplings between positions 154–265 and
201–256 (Table 4). The time trends for the individual
variants 154I–A265, M154-265 V, and V201-256E were
discordant despite positive direct coupling terms. The
reason for this may be unidirectional coupling, i.e. 154I
requires the presence of A265, but not vice versa.
Likewise, the time trends of M154-A265, 154I-265 V,
and 201I-256E were concordant despite negative direct
coupling terms.
The prevailing concordance of significant time trends
and significant couplings in our study suggests the selec-
tion of coevolving epistatic clusters. However, due to the
transmission bottlenecks [18], genetic drift may be an-
other viable explanation for the observed time trends in
the frequency of certain amino acid variants. The role of
genetic drift in HIV evolution is debated and has been
quantified to some extent at the level of intra-patient
evolution and for known transmission pairs rather than
on inter-patient level [60, 61]. Genetic drift on inter-
patient level requires inheritance of selectively neutral
substitutions. Large parts of the integrase may be under
negative selection to maintain enzymatic functionality;
nevertheless, particular positions and certain substitu-
tions of the integrase may be selectively neutral. There-
fore, we considered the possibility of genetic drift for all
time-trending substitutions by assessing whether there
Fig. 3 Amino acid variants with significant trends in frequency over time. The median frequencies of variants corresponding to the consensus B
reference sequence within each period are indicated by filled circles with blue error bars indicating the 5th–95th percentile ranges. The median
frequencies of variants differing from the consensus B reference sequence within each period are indicated by filled squares with red error bars
indicating the 5th–95th percentile ranges. The median predicted slopes are depicted in blue or red solid lines. The 5th–95th percentile ranges of
the model-predicted trends are indicated by dotted lines. Predicted slopes sl are given in units %/year. Positions are grouped by the three
functional domains of the integrase. Positions showing trends in INSTI resistance-associated variants are shaded grey. *** time trend is significant
at the P < 0.01 level, ** time trend is significant at the P < 0.05 level
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was evidence for (i) inheritance of the time-trending
substitutions and (ii) whether the time-trending substi-
tutions were selectively neutral. Ad (i): We statistically
compared the mean patristic distance of random se-
quences versus the mean patristic distance of sequences
carrying a specific time-trending substitution to investi-
gate if time-trending substitutions appeared more fre-
quently in phylogenetically closely related sequences
(Additional file 1: Table S1). Sequences carrying the
time-trending substitutions 72 V, 154I, 165I, and 265 V
had significantly smaller mean patristic distances than
random, by this indicating inheritance. Interestingly, all
of these substitutions decreased in frequency over time.
Ad (ii): First, we performed Tajima’s D test [60, 61] with
a result of D = −1.44, by this indicating negative selec-
tion. Next, we calculated the ratio of nonsynonymous
over synonymous mutations (dN/dS ratio) [60, 61], find-
ing that most regions of the integrase were under strong
negative selection, including sites 72, 154, 165, and 265
(Additional file 2: Figure S1). In summary, we could not
observe a clear contribution of genetic drift to the time
trends of the examined substitutions.
By using Sanger sequencing of bulk RT-PCR prod-
ucts with a sensitivity of approximately 30% [62, 63]
and excluding ambiguous amino acids in our analyses
we could only investigate the major virus variant
from each patient sample. Minor variants and linkage
between minor variants can only be investigated by
using more sensitive techniques like single genome
sequencing (SGS) or next generation sequencing
(NGS) [63–65]. To minimize the probability that
technical errors during RT-PCR and Sanger sequen-
cing lead to false positive predictions with regard to
coupling terms, we combined our direct coupling
analysis with a power analysis, which essentially re-
quires that an amino acid pair has to be present in
multiple sequences to be repeatedly identified by dir-
ect coupling analysis. Recently, the use of covariation
methods as a measure of coevolution has been ques-
tioned by Talavera et al. [66]. Based on a computa-
tional study, the authors point out that a strong
covariation signal is caused by a low evolutionary
rate. We therefore assessed our results accordingly
but could not find a relation between the rarity of
pairwise substitutions and high coupling terms or the
occurrence of single substitutions in couplings (Add-
itional file 3: Figure S2).
16 minor INSTI resistance mutations and 11
INSTI-selected mutations were observed as naturally
occurring in our ART-naïve study population, which
originated from the time prior to INSTI approval.
Among these resistance-associated variants, three in-
creased in frequency over time and seven covaried
with non-resistance-associated variants. The complex
Table 3 Evolutionary coupling terms for covarying positions
within the HIV-1 integrase











































Evolutionary coupling terms ecij between position i and j with P < 0.005 and
power > 0.95 are given
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interdependent evolution of these mutations might
control enzymatic activity and replication capacity in-
dependent of selective pressure through INSTIs at the
inter-patient level. Indeed, accessory drug resistance
mutations that compensate viral fitness are often
already polymorphic in drug-sensitive HIV-1, suggest-
ing that these mutations may naturally enhance viral
fitness and virulence with progression of the HIV-1
epidemic [21, 22]. INSTI-independent linkage between
non-resistance-associated sites and resistance-
associated sites or sites targeted by INSTIs can affect
the selection of resistance mutations in the presence
of INSTIs. This knowledge should be taken into ac-
count for the improvement of resistance prediction
algorithms as well as for the development and pre-
clinical evaluation of new INSTIs and ALLINIs. Dee-
per analyses of the observed resistance-associated
variants are needed to evaluate their clinical rele-
vance. In particular, those with naturally increasing
frequencies that were linked to covariation should be
investigated, i.e. L101I, T122I, and V201I. The
absence of major INSTI resistance mutations in our
ART-naïve study population underscores the suitabil-
ity of INSTIs for first-line antiretroviral regimens.
Because the analysed dataset was rather small
(n = 337), our results may require further validation
from the analysis of larger, independent datasets. Due
to the relatively small number of samples, some of
our results might not have reached statistical signifi-
cance, e.g. the temporal trend of T122 and D256.
Generally, given the small sample size, overrepresen-
tation of almost identical sequences (i.e. from trans-
mission chains) may profoundly bias any downstream
analysis of time trends and covariation patterns. To
assess whether our analyses were affected by such
sampling bias, we additionally performed them using
a reduced dataset in which clusters of closely related
sequences were replaced by one representative only.
The results obtained from the reduced dataset con-
firmed all results obtained from the full dataset.
Conclusions
Our aim was to analyse the molecular evolution of the
HIV-1 integrase prior to the approval of INSTIs and,
thus, INSTI selective pressure at the inter-patient level.
We found significant time trends in the frequency of
certain amino acid variants, suggesting ongoing adapta-
tion of the enzyme. Upon closer inspection, we found
that amino acid variants with significant time trends co-
varied with other time-trending variants. Such a linkage
may impose constraints that determine the evolutionary
Fig. 4 Significant couplings within the HIV-1 integrase. The size of the dots indicate the values of the evolutionary coupling terms ecij and are
plotted mirrored for position i against position j. The dashed horizontal and vertical lines seperate the three functional domains of the integrase
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Table 4 Direct coupling terms for specific amino acid variants at covarying positions within the HIV-1 integrase
Position i Amino acid α Position j Amino acid β eij (α, β) Time trend Minor INSTI resistance mutation INSTI-selected mutation
10 D 122 I 0.0683 *
10 E 122 I −0.0753 *
11 D 119 S −0.0940 *
11 D 154 I −0.0527 * *
11 D 154 M 0.0335 *
11 E 119 S 0.0909 *
11 E 154 I 0.0577 * *
11 E 154 M −0.0368 *
17 N 124 A 0.0690 *
17 S 124 A −0.0598 *
23 A 201 I −0.0490 *
23 A 201 V 0.0525 *
23 V 201 I 0.0432 *
23 V 201 V −0.0443 *
31 I 154 I −0.0438 *
31 V 154 I 0.0352 *
39 C 154 I −0.0329 *
39 C 201 I 0.0776 *
39 C 201 V −0.0725 *
39 S 154 I 0.0384 *
39 S 201 I −0.0859 *
39 S 201 V 0.0828 *
72 I 265 A 0.0587 *
72 I 265 V −0.0612 *
72 V 265 A −0.0622 *
72 V 265 V 0.0676 *
101 I 111 K −0.0743 *
101 I 111 T 0.0334 *
101 I 154 I −0.0462 * *
101 I 154 M 0.0645 * *
101 L 154 I 0.0606 * *
101 L 154 M −0.0695 *
112 A 124 A 0.0205 *
112 I 124 A 0.0205 *
112 I 201 I 0.0482 *
112 I 201 V −0.0538 *
112 T 124 A −0.0447 *
112 T 201 I −0.0483 *
112 T 201 V 0.0490 *
119 G 122 I 0.0576 *
119 P 122 I 0.1303 *
119 S 122 I −0.1695 * *
119 T 122 I −0.0194 *
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trajectory of the integrase and that influence the selec-
tion of INSTI resistance mutations. Our results can help
in evaluating the resistance potential of naturally occur-
ring polymorphisms and in understanding the develop-
ment of resistance in the presence of INSTIs.
Additional files
Additional file 1: Table S1. Statistics assessing whether time-trending
substitution could have resulted from inheritance. (DOCX 11 kb)
Additional file 2: Figure S1. dN/dS ratio for different regions of the
HIV-1 integrase. The red line depicts the median and the grey shaded
area the 25 to 75 percentile range. Black dots mark time-trending
positions, i.e. codons 6, 11, 72, 101, 119, 122, 124, 135, 154, 165, 201, 256,
265. A sliding window with window size 5 was applied. (EPS 542 kb)
Additional file 3: Figure S2. Relation between significant coupling
and frequency of single/pairwise substitutions. a) Relation between the
relative frequencies of substitution pairs within the MSA and the
strength of their coupling values (only significant couplings are considered).
b) Relation between the relative frequencies of single substitutions within
the MSA and their absolute frequency in significant couplings. (ZIP 133 kb)
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Table 4 Direct coupling terms for specific amino acid variants at covarying positions within the HIV-1 integrase (Continued)
Position i Amino acid α Position j Amino acid β eij (α, β) Time trend Minor INSTI resistance mutation INSTI-selected mutation
124 A 125 T 0.0266 *
124 A 125 V −0.0288 *
124 A 211 K −0.0568 *
124 A 211 R 0.0263 *
124 A 211 T 0.0294 *
124 S 125 A 0.0244 *
124 T 125 A −0.0205 *
154 I 165 I 0.0893 * *
154 I 165 V −0.0976 * *
154 I 256 D 0.0333 *
154 I 256 E −0.0369 * *
154 I 265 A 0.0520 * *
154 I 265 V −0.0484 * *
154 M 165 I −0.1011 *
154 M 165 V 0.1118 *
154 M 256 E 0.0525 *
154 M 265 A −0.0496 *
154 M 265 V 0.0482 *
157 Q 160 K −0.0632 *
157 Q 160 Q 0.0649 *
201 I 256 D 0.0623 *
201 I 256 E −0.0611 * *
201 I 265 A 0.0484 * *
201 I 265 V −0.0466 * *
201 V 256 E 0.0604 *
201 V 265 A −0.0535 *
201 V 265 V 0.0547 *
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